Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025

Core Viewpoint - Pelthos Therapeutics Inc. will hold a conference call on November 13, 2025, to discuss its third-quarter financial results for the period ending September 30, 2025 [1][2] Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on commercializing innovative therapeutic products for unmet patient needs [2] - The company's lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, was approved by the U.S. Food and Drug Administration in 2024 for the treatment of molluscum contagiosum [2]